Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Amer H. Zureikat, Ibrahim Nassour, David L Bartlett, Annissa Desilva, Lance A. Liotta, Aatur D. Singhi, Virginia Espina, Alessandro Paniccia, Samer AlMasri, Nathan Bahary, Brian A. Boone, Herbert J. Zeh, Patricia Loughran, Michael T. Lotze, Mazen S. Zenati
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Introduction Preoperative autophagy inhibition with hydroxychloroquine (HCQ) in combination with gemcitabine in pancreatic adenocarcinoma (PDAC) has been shown to be safe and effective in inducing a serum biomarker response and increase resection rat
Autor:
Rohit Das, Savreet Sarkaria, Randall E. Brand, Alessandro Paniccia, Samer AlMasri, Kenneth E. Fasanella, Melissa E. Hogg, Anil K. Dasyam, Jennifer Chennat, Asif Khalid, Kenneth K. Lee, Adam Slivka, Herbert J. Zeh, Mazen S. Zenati, Amer H. Zureikat, David L. Bartlett, Aatur D. Singhi, Kevin McGrath
Publikováno v:
Annals of Surgery. 275:e789-e795
OBJECTIVE To evaluate the significance of UDD in IPMNs. BACKGROUND The uncinate process of the pancreas has an independent ductal drainage system. International consensus guidelines of IPMNs still consider it as a branch-duct, even though it is the m
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Autor:
Brian A. Boone, Joal D. Beane, Mazen S. Zenati, Herbert J. Zeh, A. James Moser, Melissa E. Hogg, David L. Bartlett, Amr I. Al Abbas, Amer H. Zureikat
Publikováno v:
Ann Surg
OBJECTIVES: This study aims to present the outcomes of our decade-long experience of robotic pancreatoduodenectomy and provide insights into successful program implementation. BACKGROUND: Despite significant improvement inmortality over the past 30 y
Autor:
Caroline J. Rieser, David L. Bartlett, Asmita Chopra, Kenneth K.W. Lee, Sowmya Narayanan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Tracy Daum, Mazen S. Zenati, Katelyn Smith, Nathan Bahary, Vivianne Oyefusi, Ibrahim Nassour
Publikováno v:
J Surg Oncol
BACKGROUND AND OBJECTIVES Neoadjuvant chemotherapy (NAT) for pancreatic adenocarcinoma (PDAC) is increasingly being utilized. However, a significant number of patients will experience early recurrence, possibly negating the benefit of surgery. We aim
Autor:
Amer H. Zureikat, David L Bartlett, Kenneth K. Lee, Mazen S. Zenati, Nathan Bahary, Alessandro Paniccia, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
Ann Surg Oncol
Neoadjuvant therapy (NAT) is a growing strategy for patients with resectable pancreatic ductal adenocarcinoma (PDAC). Elderly patients are at increased risk of treatment withdrawal due to functional decline, and the benefit of NAT in this cohort rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3263486cc36ea0870e151d9eee750612
https://europepmc.org/articles/PMC8614241/
https://europepmc.org/articles/PMC8614241/
Autor:
Melissa E. Hogg, Amir A. Borhani, Herbert J. Zeh, Juliana Tobler, Ahmad Hamad, Mazen S. Zenati, Amer H. Zureikat, Patrick R. Varley, A. Klobuka
Publikováno v:
HPB. 21:695-701
We sought to investigate whether robotic pancreatoduodenectomy (RPD) mitigates adverse outcomes in patients with high-risk morphometric features compared to the open approach (OPD).Morphometric parameters for RPD and OPDs were measured by two blinded
Autor:
Amr Al-abbas, Melissa E. Hogg, Caroline J. Rieser, Matthew D. Neal, Amer H. Zureikat, Mazen S. Zenati, Brian A. Boone, Ahmad Hamad, Herbert J. Zeh
Publikováno v:
Annals of Surgical Oncology. 26:1503-1511
Pancreatic ductal adenocarcinoma (PDA) is associated with a hypercoagulable state, resulting in a high risk of venous thromboembolism (VTE). Risk of VTE is well established for patients receiving chemotherapy for advanced disease and during the perio
Autor:
Alessandro, Paniccia, Ana L, Gleisner, Mazen S, Zenati, Amr I, Al Abbas, Jae Pil, Jung, Nathan, Bahary, Kenneth K W, Lee, David, Bartlett, Melissa E, Hogg, Herbert J, Zeh, Amer H, Zureikat
Publikováno v:
Annals of surgical oncology. 27(8)
Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify pre
Autor:
Melissa E. Hogg, Amer H. Zureikat, Mazen S. Zenati, Mark D. Girgis, Ahmad Hamad, Jonathan C. King, Herbert J. Zeh
Publikováno v:
Annals of surgery. 274(3)
OBJECTIVE Compare oncologic outcomes after open and robotic pancreatic resections for pancreatic adenocarcinoma (PDAC). SUMMARY OF BACKGROUND DATA Receipt of adjuvant chemotherapy improves survival after resected PDAC. Complications after pancreatect